In an effort to determine the value of phytoestrogens in clinical practice, Austrian researchers analyzed six systematic reviews and meta-analyses of 25 randomized, controlled trials (RCTs).
In an effort to determine the value of phytoestrogens in clinical practice, Austrian researchers analyzed six systematic reviews and meta-analyses of 25 randomized, controlled trials (RCTs).
Generally, they found the results contradictory and the findings of the meta-analyses to demonstrate no statistically significant reduction in vasomotor symptoms. However, one systematic review of five RCTs found that in a select population of women-those in early and natural postmenopause with mild-to-moderate vasomotor symptoms-five out of the five studies found a significant reduction in hot flashes. And a meta-analysis of 21 studies found a significantly reduced risk of breast cancer in past users of phytoestrogens.
While various RCTs report favorable effects on bone mineral density, vasodilation, platelet aggregation, insulin resistance, and serum concentrations of triglycerides, high-density lipoprotein, and low-density lipoprotein, no study proves an actual protective effect against the endpoints of breast cancer, bone fracture, or cardiovascular events.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More